Bengaluru: Sagility Limited (NSE: SAGILITY, BSE: 544282), a global healthcare operations partner serving U.S. payers, providers and pharmacy benefit managers, reported strong financial performance for the quarter ended September 30, 2026, with Sagility Q2 FY27 revenue rising 22.5% year-on-year to ₹20,321 million.
The company reported 12.2% year-on-year revenue growth in constant currency (CC) terms during Sagility Q2 FY27.
- Adjusted EBITDA stood at ₹5,353 million, representing 26.3% of revenue and growing 23.0% year-on-year.
- Adjusted PAT for Sagility Q2 FY27 stood at ₹3,254 million, or 16.0% of revenue, marking an 8.1% year-on-year increase.
Sagility Q2 FY27 Financial Highlights
For the quarter ended September 30, 2026, Sagility reported:
- Revenue of ₹20,321 million (US$212.6 million), up 22.5% year-on-year and 12.2% in constant currency terms.
- Organic year-on-year revenue growth of 22.2%, or 11.9% in constant currency terms.
- Adjusted EBITDA of ₹5,353 million (US$56.0 million), representing 26.3% of revenue and growing 23.0% year-on-year.
- Adjusted PAT of ₹3,254 million (US$34.0 million), representing 16.0% of revenue and growing 8.1% year-on-year.
- Basic earnings per share (EPS) of ₹0.61, up 13.3% year-on-year.
- Adjusted basic EPS of ₹0.70, up 8.1% year-on-year.
The Sagility Q2 FY27 results reflect revenue growth alongside higher adjusted EBITDA, while adjusted PAT also increased during the quarter.
Sagility H1 FY27 Financial Performance
For the half year ended September 30, 2026, Sagility reported revenue of ₹39,956 million (US$420.4 million), representing year-on-year growth of 25.0% and 13.7% in constant currency terms.
Organic revenue growth during the first half of FY27 was 24.7% year-on-year, or 13.4% in constant currency terms.
- Adjusted EBITDA for H1 FY27 stood at ₹10,069 million (US$105.9 million), representing 25.2% of revenue and growing 25.2% year-on-year.
- Adjusted PAT stood at ₹5,951 million (US$62.6 million), representing 14.9% of revenue and growing 18.9% year-on-year.
- Basic EPS for H1 FY27 was ₹1.07, up 25.4% year-on-year, while adjusted basic EPS stood at ₹1.27, up 18.9% year-on-year.
Sagility Q2 FY27 Business Highlights
During Sagility Q2 FY27, the company secured $40.2 million in annual contract value (ACV) from 31 existing clients and one new logo.
Sagility added 28 client groups during H1 FY27, including clients acquired through the CareSeed acquisition. This took the company’s total active client group base to 105.
The company also reported growing AI momentum, with new statement of work (SOW) wins, more production deployments and AI-led go-to-market initiatives enabling faster solutioning.
Sagility acquired Chirok Health LLC to accelerate growth in its Provider segment.
The acquisition adds specialised clinical documentation integrity (CDI) and coding capabilities, extending Sagility’s end-to-end revenue cycle management (RCM) offering and creating new growth opportunities.
- At the end of Sagility Q2 FY27, the company had 51,486 employees.
- As of September 30, 2026, Sagility had a presence across five countries with 28 delivery centres.
- The company also declared an interim dividend of ₹0.15 per share.
Sagility Q2 FY27 Rewards and Recognitions
Sagility received several recognitions during the period, including:
- Recognised as a Leader in Avasant’s Healthcare Payer Business Process Transformation 2026 RadarView™.
- Sagility’s SmarTec Nurse Assist solution won the 2026 Stratus Awards for Cloud Computing by Business Intelligence Group in the SaaS category.
- Received the Voice of the Customer Honor – HLS Services Specialist.
- Sagility India ranked 57th among the 100 Best Large Workplaces in Asia 2026 by Great Place to Work®.
- Sagility India was recognised among the Top 10 India’s Best Workplaces for Women 2026.
- Sagility India earned Great Place To Work® Certification™ for the second consecutive year.
- Won a Bronze Stevie® Award in AI Adoption with Headcount Growth.
- Sagility won the Golden Peacock Award for ESG.
Ramesh Gopalan, Managing Director and Group CEO, said, “Our performance in the first half of FY27 reflects broad-based momentum across the business. Our pipeline is healthy with larger deals and a growing set of opportunities with Blues and mid-market plans. Our AI solutions are gaining traction, with new SOW wins and more solutions moving into production.
CareSeed is now integrated into our Clinical Practice, adding depth to our healthcare quality capabilities and our recent acquisition of Chirok will accelerate our growth in the provider segment, strengthening our end-to-end provider RCM capabilities.
As we enter the second half, our priority is disciplined execution through the AEP and Open Enrolment season, while investing in the capabilities that will drive our next phase of growth.”
Srinivas Mattapalli, Group Chief Financial Officer, added, “Q2 FY27 was a strong quarter with healthy growth, robust cash generation and our highest adjusted EBITDA margin in six quarters, reflecting disciplined execution, operating leverage and delivery efficiencies. Our revenue trajectory demonstrates the resilience of the operating model as we enter the seasonally stronger H2.
Underscoring our confidence in the business and our commitment to shareholder returns, the Board has declared an interim dividend of ₹0.15 per share, up from ₹0.05 in the previous interim. We will continue to invest selectively in technology, AI and domain-led growth to create long-term value for our stakeholders.”
Sagility is a healthcare operations partner that helps payers, providers and pharmacy benefit managers reduce costs, improve quality, and enhance member and provider experiences.
With more than 25 years of exclusive focus in healthcare, Sagility combines domain expertise with technology-led transformation, embedding analytics, automation and AI directly into operations while ensuring compliance with complex regulatory and clinical requirements.
Serving more than 100 healthcare clients, including seven of the top U.S. health plans, Sagility delivers end-to-end operational transformation at scale through a model built on accountability, transparency and measurable outcomes.
